Maria Morales-Villa

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Differential expression of cancer-related genes supports prediction of poor response to first-line treatments in T-ALL pediatric patients with high minimal residual disease.

Differential expression of cancer-related genes supports prediction of poor response to first-line treatments in T-ALL pediatric patients with high minimal residual disease.

Journal: Molecular oncology

Published: May 16, 2025

Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.

Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.

Journal: British journal of haematology

Published: May 05, 2025

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.

Journal: NPJ precision oncology

Published: October 18, 2023

Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia.

Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia.

Journal: International journal of molecular sciences

Published: May 19, 2023

The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib.

The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib.

Journal: Molecular carcinogenesis

Published: April 11, 2023

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.

Journal: British journal of haematology

Published: March 19, 2023

SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.

SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.

Journal: British journal of haematology

Published: December 29, 2022

A Dual Role for FADD in Human Precursor T-Cell Neoplasms.

A Dual Role for FADD in Human Precursor T-Cell Neoplasms.

Journal: International journal of molecular sciences

Published: October 31, 2022

FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications.

FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications.

Journal: Cancers

Published: August 12, 2019

Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells.

Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells.

Journal: Carcinogenesis

Published: May 17, 2019

S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.

S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.

Journal: Carcinogenesis

Published: December 11, 2018

Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.

Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.

Journal: Oncogene

Published: July 06, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026